Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2018 (pdf):
Abstract (in Norwegian)
Download in single page format - double page (broad) format

Publication overview

Current news and events

Jan Terje Andersen head of hiv research program receiving 19 mill NOK

Jan Terje Andersen

A consortium of University of Oslo, The International AIDS Vaccine Initiative (IAVI) and the Translational Health Science and Technology Institute (THSTI) has been granted 19.09 MNOK (about U.S. $2.2M) for a period of three years from the Research Council of Norway through the GLOBVAC (Global Health Vaccination and Research) program for the development of broadly neutralizing antibodies as HIV prevention products. Teams on three continents will work to engineer and optimize antibodies to extend their half-life, an improvement designed to increase the duration of antibody activity and potentially lead to longer intervals between protective doses. The consortium is led by UiO.

The program is headed by Jan Terje Andersen, associate professor at the University of Oslo and leader of The Laboratory of Adaptive Immunity and Homeostasis at the Department of Immunology at Oslo University Hospital.

Announcement from Helse Sør-Øst:Call for applications for research-based innovation

Funding of research-based innovation in Helse Sør-Øst is intended to provide financial opportunities for good ideas that have been developed through research activities at the hospitals and private institutions in the region. The ideas must be based on research results with the potential for commercialisation and/or benefit for society. 

Application deadline is Thursday, September 5th 2019, 16:00.

Funding of ideas and inventions in this context involves financing an innovation process, that is to say that the innovation funds will be used to support activities that are linked to defined milestones in the innovation process and which ensure that the development of the idea is continued towards implementation.

Announcement from Helse Sør-Øst:Call for applications for health research

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF) hereby announces a call for applications for health research in this region. The total funding available for this call is approximately 130 million Norwegian kroner.

Application deadline is Thursday, September 5th 2019, 16:00.

The following research categories are available for funding of projects starting in 2020:
PhD fellowships, Postdoctoral fellowships, Career fellowships, Support for clinical research projects, Open project support

Marte Sneeggen identifies new mechanism how a tumor suppressor prevents metastasis

Marte Sneeggen
First author

In a recent article in Nature Communications, published online on the 28thof June, 2019, PhD student Marte Sneeggen and her coworkers at the Institute for Cancer Research and the Center for Cancer Cell Reprogramming (CanCell) identify a new mechanism how the tumor suppressor WDFY2 prevents metastasis by controlling recycling of the matrix metalloproteinase MT1-MMP

One of the most serious complications of cancer is the ability of tumors to form metastases. In most cases, the primary tumor can be treated, whereas metastasis is still the major cause of cancer mortality.

Units and subpages

View all subunitsHide all subunits